U.S. markets closed
  • S&P Futures

    4,241.00
    +9.50 (+0.22%)
     
  • Dow Futures

    33,851.00
    +92.00 (+0.27%)
     
  • Nasdaq Futures

    14,300.50
    +37.50 (+0.26%)
     
  • Russell 2000 Futures

    2,307.80
    +7.50 (+0.33%)
     
  • Crude Oil

    73.07
    -0.01 (-0.01%)
     
  • Gold

    1,775.90
    -7.50 (-0.42%)
     
  • Silver

    25.92
    -0.20 (-0.75%)
     
  • EUR/USD

    1.1923
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • Vix

    16.32
    -0.34 (-2.04%)
     
  • GBP/USD

    1.3954
    -0.0010 (-0.07%)
     
  • USD/JPY

    111.0300
    +0.0680 (+0.06%)
     
  • BTC-USD

    32,847.37
    -962.56 (-2.85%)
     
  • CMC Crypto 200

    788.49
    -21.70 (-2.68%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,873.01
    -1.88 (-0.01%)
     

Calculating The Intrinsic Value Of Humanigen, Inc. (NASDAQ:HGEN)

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.

How far off is Humanigen, Inc. (NASDAQ:HGEN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the forecast future cash flows of the company and discounting them back to today's value. We will use the Discounted Cash Flow (DCF) model on this occasion. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Humanigen

The method

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$254.5m

US$215.1m

US$114.9m

US$25.5m

US$95.0m

US$69.1m

US$56.3m

US$49.3m

US$45.3m

US$43.0m

Growth Rate Estimate Source

Analyst x5

Analyst x5

Analyst x4

Analyst x3

Analyst x3

Est @ -27.34%

Est @ -18.54%

Est @ -12.38%

Est @ -8.07%

Est @ -5.05%

Present Value ($, Millions) Discounted @ 6.5%

US$239

US$190

US$95.2

US$19.8

US$69.5

US$47.4

US$36.3

US$29.8

US$25.8

US$23.0

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$775m

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.5%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$43m× (1 + 2.0%) ÷ (6.5%– 2.0%) = US$979m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$979m÷ ( 1 + 6.5%)10= US$523m

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$1.3b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$18.1, the company appears about fair value at a 18% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Humanigen as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.5%, which is based on a levered beta of 0.949. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Humanigen, we've compiled three essential aspects you should consider:

  1. Risks: Every company has them, and we've spotted 3 warning signs for Humanigen (of which 2 don't sit too well with us!) you should know about.

  2. Future Earnings: How does HGEN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.